MoneyWorks4Me

Unichem Laboratories Ltd (UNICHEMLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506690 NSE: UNICHEMLAB Pharmaceuticals & Drugs | Small Cap | Unichem Laboratories Share Price

₹572.95 38.30 (7.16%)

As on 23-Sep'26 16:59

Unichem Laboratories Ltd (UNICHEMLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506690 NSE: UNICHEMLAB Pharmaceuticals & Drugs | Small Cap | Unichem Laboratories Share Price

₹572.95 38.30 (7.16%)

As on 23-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹3,764 Cr.
Current Price
₹573
52-Week Low / High
₹280 / 686
TTM EPS
₹43.3
TTM Sales
₹2,308 Cr.
Book Value per Share
₹391
P/E Ratio
12.35
Industry PE
54.8
Price to Book (P/B)
1.37
Higher than its 5-year historical median
Price to Sales (P/S)
1.63
Lower than its 5-year historical median
EV/EBITDA
13.11
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
9.81%
Outperforms industry median
Return on Capital Employed (ROCE)
10.68%
In line with industry median
Return on Assets (ROA)
6.97%
Operating Profit Margin
8.6%
Net Profit Margin
11.48%
Gross Profit Margin
9.8%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-18.63%
Operating Profit Growth (1 Year)
-
-30.47%
Net Profit Growth (1 Year)
-
83.86%
Asset Quality
Promoter Holding
70.22%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹2,739 Cr.
Equity
₹14.1 Cr.
Face Value
₹2
All Time Low / High
₹1.50 / 949.85

Unichem Laboratories stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Overvalued

Price Trend

Strong
Q.1 Is Unichem Laboratories Ltd a good quality company?
Unichem Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Unichem Laboratories Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Unichem Laboratories Ltd vs industry peers?
Unichem Laboratories Ltd revenue CAGR is 12.26%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Unichem Laboratories Ltd?
Promoters hold 70.22% of the Unichem Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Unichem Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 7.3% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Unichem Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % -8.3%-6.1%-0.8%-2.3%2.5%-3.1%-10.2%-3.4%7.7%8.4%-
Value Creation
Index
-1.6-1.4-1.1-1.2-0.8-1.2-1.7-1.2-0.5-0.4-

Growth Parameters

Sales 5766669689041,1249431,0721,4421,7361,4121,394
Sales YoY Gr.-15.6%45.3%-6.5%24.3%-16.1%13.7%34.5%20.4%-18.6%-
Adj EPS -6.4-17.80.9-13.66.5-9.5-34.6-9.620-1.423.6
YoY Gr.-NANA-1677.9%NA-244.9%NANANA-107.1%-
BVPS (₹) 124.3392.6387.6375.3382378336.9325.5348.7372.3373.1
Adj Net
Profit
-58.2-1256-95.545.9-66.5-243-67.9140-10166
Cash Flow from Ops. 141-66.3-251-41.8-32.6-158-117-41.672.352.6-
Debt/CF from Ops. 0-00-0.40-0.8-0.9-1.51.51-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 10.5%4.7%9.6%-18.6%
Adj EPS NA-173.7%NA-107.1%
BVPS13%-0.5%3.4%6.8%
Share Price 8% 17.1% 11.2% 16%

Key Financial Parameters

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity %
-5.4-6.40.2-3.61.7-2.5-9.6-2.95.9-0.46.3
Op. Profit
Mgn %
-5.4-19.1-5-9.98.5-4-8.73.514.63.73
Net Profit
Mgn %
-10.1-18.80.6-10.64.1-7.1-22.7-4.78.1-0.711.9
Debt to
Equity
000000.1000.10-
Working Cap
Days
419371298385344444421339319408192
Cash Conv.
Cycle
181152122175154245243191190260138

Valuation of Unichem Laboratories - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales6988151,1801,1041,2351,2701,3431,7852,1112,202
Operating Expenses + 7399461,2641,1551,1441,1971,3891,6981,8462,018
Manufacturing Costs145175319305285271297335351296
Material Costs189275364309302357482638751934
Employee Cost 169201239273307330356403402397
Other Costs 236296342268250238252322342391
Operating Profit -41-132-83-519173-4687265184
Operating Profit Margin (%) -5.9%-16.2%-7.1%-4.6%7.4%5.7%-3.4%4.9%12.5%8.4%
Other Income + 6619891504839323563
Exceptional Items 000000-39-580202
Interest 38885617232132
Depreciation 445167828491113123125125
Profit Before Tax -83-130-60-485122-176-85155292
Tax -123-341217-112691740
Profit After Tax -71-133-26-603433-202-94138253
PAT Margin (%) -10.1%-16.3%-2.2%-5.5%2.8%2.6%-15.1%-5.3%6.5%11.5%
Adjusted EPS (₹)12.0361.8-3.4-8.64.94.7-28.7-13.319.535.9
Dividend Payout Ratio (%)25.10%1.40%-118.30%-46.80%82.10%85.20%0%0%0%0%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 1,0622,6792,6162,5272,5492,6082,4232,4352,4452,712
Share Capital 18.1814.0714.0814.0814.0814.0814.0814.0814.0814.08
Reserves 1,0442,6652,6022,5122,5352,5942,4092,4212,4312,697
Debt +98151200184101305272193401455
Long Term Debt000008964386139
Short Term Debt98150200184101216208155340415
Minority Interest0000000000
Trade Payables211226221250210183291351387357
Others Liabilities 15013496181252219197288310184
Total Liabilities 1,5213,1903,1333,1423,1123,3143,1833,2683,5443,707

Fixed Assets

Net Fixed Assets +4875748068668809901,2571,2521,3001,213
Gross Block5616909761,0981,1941,3801,7501,9201,9941,992
Accumulated Depreciation74115170232313390494667694779
CWIP 2502389233056749414712331100
Investments 149019265503922642100
Inventories282273339397538600625736989975
Trade Receivables315277436390250495589642779829
Cash Equivalents 1668120123482114185158118295
Others Assets 157245332375401357378355328296
Total Assets 1,5213,1903,1333,1423,1123,3143,1833,2683,5443,707
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity + 68-112-3282033-260-8514-74
PBT 1413,241-57-485122-176-85155292
Adjustment 53-3,2087196680133197149-73
Changes in Working Capital -99-147-26554-70-354-29-92-294-208
Tax Paid -281-12-4-14-8-12-6-16-8
Cash Flow From Investing Activity + -1281,648-286-36-7410220350-241192
Capex -147-158-192-380-287-127-38-14-135160
Net Investments 12,480-14729618720423765-834
Others 18-673534827254-1-2328
Cash Flow From Financing Activity + 59-881-2-62-121191-81-1061842
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -23-0-000-10-26-2625-42
Interest Paid -3-8-9-7-4-5-16-22-20-25
Dividend Paid -1-33-42-34-29-28-28-0-0-0
Others 86-84049-21-88234-11-5817969
Net Cash Flow -0655-616-78-1623436-42-64198
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)-7.02-7.11-0.97-2.341.351.28-8.04-3.865.649.81
ROCE (%)-7.36-6.1-1.85-1.462.111-5.6-2.316.3410.68
Asset Turnover Ratio0.490.350.370.350.40.40.410.550.620.61
PAT to CFO Conversion(x)N/AN/AN/AN/A0.97-7.88N/AN/A-0.050.02
Working Capital Days
Receivable Days139.90132.60110.30136.6094.60107.20147.30125.80122.90133.20
Inventory Days133.80124.2094.60121.60138.10163.60166.50139.20149.10162.80
Payable Days362.20290224.30278.90278201.10179.30183.70179.40145.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Unichem Laboratories Ltd FAQs

The current trading price of Unichem Laboratories on 23-Sep-2026 16:59 is ₹573.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Unichem Laboratories stood at ₹3,764.2 Cr

The latest P/E ratio of Unichem Laboratories as of 22-Sep-2026 is 22.63.

The latest P/B ratio of Unichem Laboratories as of 22-Sep-2026 is 1.43.

The 52-week high of Unichem Laboratories is ₹686.0 and the 52-week low is ₹280.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Unichem Laboratories is ₹1,394 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Unichem Laboratories Ltd is a below average quality company.

The key valuation ratios of Unichem Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Unichem Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Unichem Laboratories Ltd

Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business.

The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.

Headquartered in Mumbai, the company operates at five manufacturing locations in Roha (Maharashtra), Goa, Ghaziabad (Uttar Pradesh), Pithampur (Madhya Pradesh) and Baddi (Himachal Pradesh).

The company’s manufacturing facilities have received approval from various international agencies namely UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The manufacturing plants have also received ISO 9001:2000 and ISO 14001:2004 certifications for quality management.

Unichem also operates a research and development facility located at Jogeshwari (Mumbai). This facility conducts research in area of Novel Drug Delivery Systems (NDDS) and develops non-infringing routes for the manufacture of products directed at the regulated markets.

Milestones

1944- Unichem was commissioned by Late Amrut Mody.

1952- The company forayed into exporting activities.

1953- Unichem entered into hormonal products segment. The same year it launched UNIPROGESTIN.

1962- The company collaborated with foreign entity UCB for bulk-drugs. It set up its first formulation plant at Jogeshwari. The company got listed at Bombay Stock Exchange. Unichem launched OESTROGEN and Progestin.

1963- The company entered co-marketing of formulations tie up with Uni Sankyo.

1968- Unichem set up a formulation plant at Ghaziabad.

1970- As part of back integration strategy, the company commissioned manufacturing of Anti-TB Drugs.

1972- As an acknowledgement for Late Amrut Mody’s  pioneering effort in Indian pharma industry, he was awarded Padma Bhushan.

1973- Unichem's research laboratory was recognised for Phd work by Bombay University. Unichem's R&D centre was recognised by Department of Science and Technology.

1976- The company set up a fine chemicals unit at Roha.

1978- Unichem commissioned its Roha bulk drug plant.

1979- The company received its first clearance from drug authorities for NEFEDIFINE.

1983- Unichem received the USFDA approval for hydrochlorothiazide manufactured at the Jogeshwari plant. The company introduced Anti-TB - Isoniazid, Rifampicin in white tablet form for the first time in India.

1984- UNISEARCH was established in collaboration with Upjohn. The company forayed anti-biotic segment and launched Ampoxin (Ampicillin and Cloxacillin combination).

1987- The company entered the animal health care business.

1994-1999- Unichem underwent thorough restructuring and transformation in line with future growth strategies.

1996- Two companies namely Unichem Exports and Unisearch was merged with Unichem Laboratories.

1997- The company’s formulation plant located at Goa was commissioned. It set up new corporate office set up at Unichem Bhavan Jogeshwari, Mumbai.

1998- The company’s formulations plant located at Baddi was fully operational.

1997-2000- The company implemented BaaN ERP.

1999- Unichem set up a modern multipurpose bulk drug plant located at Roha. Molecular generics division was launched.

2000- The drug major received South African Health Authority and UK MCA (MHRA) certifications for Goa and Baddi Plants

2001- Unichem set up new research and development centre at Mumbai. The same year it also set up New Biosciences R&D Centre located at Bangalore that would conduct research work in Bio-technology

2002- It formed a joint venture in UK called Niche Generics.

2002-2003- The company divested its animal healthcare division. It established subsidiaries in South Africa and Brazil. The company also undertook modernization of formulations plant located at Ghaziabad.

2004- Unichem conducted restructuring of Unisearch and launched of Unisearch CD Division.

2005- The company set up of new pharma technology development center located at Goa. Unichem Baddi Unit II plant was commissioned. It acquired API manufacturing unit at Pithampur

2006- The company received USFDA certification for the Goa Plant. It launched specialities division. In the same year it acquired 100% stake in Niche Generics, United Kingdom.

2007- Unikare division launched that catered to Dermatology and Allied therapies segment.

Future Strategies

Unichem will continue to work on the therapeutic segments and will develop cost effective processes for the existing molecules. It will also focus on develop new drug delivery systems and new products for international business.

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now